Free Newsletter
Cancer researchers ID new drug target
Researchers at Children's Hospital in Boston have identified a protein that appears to play a key role in about 15 percent of all cancers, offering a new drug target that could be particularly effective for hard-to-treat patients.
George Daley, Srinivas Viswanathan and Richard Gregory say that the protein LIN28 pushes a cell to a cancerous state and appears abundant in advanced cancers like liver cancer, ovarian cancer and acute myeloid leukemia, according to a report in The Medical News. A drug that inhibits LIN28 could have wide application, they believe.
"Linking this protein to advanced cancer is a very exciting new result," says Daley, Director of Stem Cell Transplantation at Children's. "It gives us a new target to attack, especially in the most resistant and hard-to-treat cases. LIN28 is a fascinating protein that acts both in stem cells and cancers, and is teaching us that cancer is often a disease of stem cells."
- read the report from The Medical News
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: